eMedicine Specialties > Pulmonology > Interstitial Lung Diseases
Eosinophilic Granuloma (Histiocytosis X): Differential Diagnoses & Workup
Updated: Mar 3, 2008
- Overview
- Differential Diagnoses & Workup
- Treatment & Medication
- Follow-up
- Multimedia
Differential Diagnoses
Other Problems to Be Considered
- Tuberous sclerosis
- Lymphangioleiomyomatosis (LAM): Patients with PLCH frequently present to medical attention with spontaneous pneumothoraces. Lymphangioleiomyomatosis is a disorder that exclusively affects young women and is characterized by cystic, emphysematous dilation of the terminal airways and shares this predisposition. It may be mistaken for PLCH on a chest radiograph or high-resolution CT (HRCT) scan of the chest.
Workup
Laboratory Studies
- Results from routine laboratory testing are nonspecific.
- Peripheral eosinophilia is not observed.
Imaging Studies
- Chest radiographs characteristically reveal bilateral, symmetric, ill-defined nodules and reticulonodular infiltrates. As the disease progresses, cystic lesions appear. An upper-zone predominance of radiographic findings with sparing of the costophrenic angles is typically observed.
- Cystic lesions can be of various sizes and thin or thick walled.
- Lung volume is normal or increased.
- Honeycombing indicates advanced disease.
- Bony lesions may occur on the ribs or any other site.
- Hilar or mediastinal adenopathy is rare and should prompt the consideration of sarcoidosis or malignancy.
- Pleural effusion is uncommon.
- HRCT of the chest may be virtually diagnostic in the appropriate clinical setting. Pathognomonic findings include nodules and cysts, predominantly in the mid and upper lung zones, with sparing of the costophrenic regions. The nodules may be cavitary and variable in size. Likewise, the cysts may be of various diameters and wall thicknesses. A broad differential diagnosis must be considered in the following situations:
- If only nodules are present on HRCT, the findings are nonspecific, and a number of other granulomatous disorders cannot be excluded radiographically.
- When cysts are an isolated finding, LAM must be considered as well. Unlike PLCH, LAM is usually uniformly distributed throughout the lungs. Sparing of the costophrenic angles supports a diagnosis of PLCH.
- Emphysema is usually distinguishable, as walls do not surround the cystic spaces found in emphysema. However, extensive emphysema is sometimes difficult to differentiate from PLCH.
Other Tests
- Pulmonary function testing can demonstrate all patterns of abnormality: Normal, restrictive, obstructive, or mixed.
- Most patients have normal or near-normal total lung capacity with near-normal spirometry findings.
- Gas exchange, as measured by the diffusing capacity for carbon monoxide, is generally reduced.
- In rare cases, patients have reversible airflow limitation.
- Gas exchange abnormalities may be present at rest. Although such abnormalities are most pronounced with exercise, most patients have a normal gradient of alveolar-arterial partial pressures.
- Pulmonary exercise testing may demonstrate decreased exercise capacity with reduced oxygen utilization. Gas exchange, ventilatory, and pulmonary vascular abnormalities may also be present. Therefore, exercise limitation is generally multifactorial.
Procedures
- Analysis of bronchioalveolar lavage (BAL) fluid is sometimes diagnostic.
- A greater than 5% increase in the number of Langerhans cells in BAL specimens is almost pathognomonic for PLCH. Although this finding is highly specific, it is not particularly sensitive.
- Langerhans cells can be recognized by their characteristic staining for S-100 protein or peanut agglutination antigen.
- These cells are CD1a-positive, and may also be identified by a specific monoclonal antibody (MT-1).
- Although the disease is present in a patchy distribution, sometimes transbronchial biopsy may be diagnostic if sampling is done in a number of areas and sufficient tissue is obtained.
- Immunostaining for Langerhans cells (CD1a) improves the sensitivity and specificity of the biopsy sample.
- The diagnostic yield is approximately 10-40%.
- Open or thoracoscopic lung biopsy is the most sensitive and specific diagnostic modality, and is generally recognized as the criterion standard.
- In addition to immunostaining, electron microscopy of tissue samples may be performed.
- Langerhans cells demonstrate the characteristic intracytoplasmic Birbeck granules. These are found in all Langerhans cells, but they are present in increased numbers in the pathologic Langerhans cells found in the lesions of PLCH.
Histologic Findings
The earliest lesions consist of Langerhans cells grouped around the small airways. These inflammatory lesions expand to form granulomatous nodules composed of Langerhans cells as well as eosinophils, macrophages, lymphocytes, plasma cells, and fibroblasts.
In addition to looking for the typical morphologic features of Langerhans cells, immunostaining for S-100 and CD1a may also be useful. Electron microscopy helps in identifying Langerhans cells by demonstrating the presence of diagnostic pentilaminar cytoplasmic inclusion bodies, or Birbeck granules (x-bodies).
Of note, eosinophils may not always be present. Therefore, the name eosinophilic granuloma, despite being a commonly accepted term, is a misnomer.
Granulomas are centered on distal bronchioles. Evidence of pulmonary vascular involvement and respiratory bronchiolitis are often present, as well as infiltration and destruction of airway walls. As the disease progresses, cavitation occurs as a result of this destruction. The nodule fibroses, eventually forming a stellate scar.
More on Eosinophilic Granuloma (Histiocytosis X) |
| Overview: Eosinophilic Granuloma (Histiocytosis X) |
Differential Diagnoses & Workup: Eosinophilic Granuloma (Histiocytosis X) |
| Treatment & Medication: Eosinophilic Granuloma (Histiocytosis X) |
| Follow-up: Eosinophilic Granuloma (Histiocytosis X) |
| Multimedia: Eosinophilic Granuloma (Histiocytosis X) |
| References |
| Further Reading |
| « Previous Page | Next Page » |
References
Gaensler EA, Carrington CB. Open biopsy for chronic diffuse infiltrative lung disease: clinical, roentgenographic, and physiological correlations in 502 patients. Ann Thorac Surg. Nov 1980;30(5):411-26. [Medline].
Colby TV, Lombard C. Histiocytosis X in the lung. Hum Pathol. Oct 1983;14(10):847-56. [Medline].
Thomeer M, Demedts M, Vandeurzen K; VRGT Working Group on Interstitial Lung Diseases. Registration of interstitial lung diseases by 20 centres of respiratory medicine in Flanders. Acta Clin Belg. May-Jun 2001;56(3):163-72. [Medline].
Watanabe R, Tatsumi K, Hashimoto S, Tamakoshi A, Kuriyama T,. Clinico-epidemiological features of pulmonary histiocytosis X. Intern Med. Oct 2001;40(10):998-1003. [Medline].
Vassallo R, Ryu JH, Schroeder DR, Decker PA, Limper AH. Clinical outcomes of pulmonary Langerhans'-cell histiocytosis in adults. N Engl J Med. Feb 14 2002;346(7):484-90. [Medline].
Delobbe A, Durieu J, Duhamel A, Wallaert B. Determinants of survival in pulmonary Langerhans' cell granulomatosis (histiocytosis X). Groupe d'Etude en Pathologie Interstitielle de la Société de Pathologie Thoracique du Nord. Eur Respir J. Oct 1996;9(10):2002-6. [Medline].
Alalawi R, Whelan T, Bajwa RS, Hodges TN. Lung transplantation and interstitial lung disease. Curr Opin Pulm Med. Sep 2005;11(5):461-6. [Medline].
Aricò M. Langerhans cell histiocytosis in adults: more questions than answers?. Eur J Cancer. Jul 2004;40(10):1467-73. [Medline].
Chaowalit N, Pellikka PA, Decker PA, Aubry MC, Krowka MJ, Ryu JH, et al. Echocardiographic and clinical characteristics of pulmonary hypertension complicating pulmonary Langerhans cell histiocytosis. Mayo Clin Proc. Oct 2004;79(10):1269-75. [Medline].
Crausman RS, Jennings CA, Tuder RM, Ackerson LM, Irvin CG, King TE Jr. Pulmonary histiocytosis X: pulmonary function and exercise pathophysiology. Am J Respir Crit Care Med. Jan 1996;153(1):426-35. [Medline].
Dacic S, Trusky C, Bakker A, Finkelstein SD, Yousem SA. Genotypic analysis of pulmonary Langerhans cell histiocytosis. Hum Pathol. Dec 2003;34(12):1345-9. [Medline].
King TE, Crausman RS. Pulmonary histiocytosis X. In: Fishman AP, ed. Fishman's Pulmonary Diseases and Disorders. Vol 1. 3rd ed. New York, NY: Mc-Graw Hill; 1998:1163-70.
Sundar KM, Gosselin MV, Chung HL, Cahill BC. Pulmonary Langerhans cell histiocytosis: emerging concepts in pathobiology, radiology, and clinical evolution of disease. Chest. May 2003;123(5):1673-83. [Medline].
Tazi A. Adult pulmonary Langerhans' cell histiocytosis. Eur Respir J. Jun 2006;27(6):1272-85. [Medline].
Vassallo R, Ryu JH. Pulmonary Langerhans' cell histiocytosis. Clin Chest Med. Sep 2004;25(3):561-71, vii. [Medline].
Keywords
eosinophilic granulomatosis, EG, pulmonary histiocytosis X, PHX, pulmonary Langerhans cell histiocytosis, PLCH, pulmonary histiocytosis, histiocytosis, cigarette smoking, end-stage fibrotic lung disease, fibrotic lung disease
Differential Diagnoses & Workup: Eosinophilic Granuloma (Histiocytosis X)